Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.

scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for the treatment of congestion from fluid overload in adults with NYHA II and III chronic ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

There are many benefits to subcutaneous administration vs IV, McCreary said. “You don’t need to start an intravenous line, so you avoid the line kit and the nursing time needed for that.

Subcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab.